Patents by Inventor Jing-Xing YANG

Jing-Xing YANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION COMPRISING TOLL-LIKE RECEPTOR AGONIST AND STIMULATOR OF INTERFERON GENES AGONIST AND USE THEREOF
    Publication number: 20240115681
    Abstract: Provided is a pharmaceutical composition including an active pharmaceutical ingredient, a toll-like receptor (TLR) agonist, a stimulator of interferon genes (STING) agonist, and a pharmaceutically acceptable carrier. Also provided are a method for inducing immune response and a method for treating or preventing cancer or an infectious disease, including administering an effective amount of the pharmaceutical composition to a subject in need thereof.
    Type: Application
    Filed: September 28, 2023
    Publication date: April 11, 2024
    Applicant: National Health Research Institutes
    Inventors: Tsung-Hsien Chuang, Jing-Xing Yang, Jen-Chih Tseng, Zaida Nur Imana, Ming-Hsi Huang, Guann-Yi Yu
  • CpG-oligodeoxynucleotide compounds in combination with immune modulators for cancer immunotherapy
    Patent number: 11898147
    Abstract: The present invention discloses a combinational therapy for enhancing efficacy of immune checkpoint blockade for tumors with immune suppressive microenvironment. More specifically, this combination therapy involves the treatment of cancer through immune checkpoint inhibitors and CpG-oligodeoxynucleotides.
    Type: Grant
    Filed: September 6, 2021
    Date of Patent: February 13, 2024
    Assignee: NATIONAL HEALTH RESEARCH INSTITUTES
    Inventors: Tsung-Hsien Chuang, Jen-Chih Tseng, Jing-Xing Yang, Yi-Ling Liu
  • CpG-oligodeoxynucleotide compounds in combination with immune modulators for cancer immunotherapy
    Publication number: 20230075652
    Abstract: The present invention discloses a combinational therapy for enhancing efficacy of immune checkpoint blockade for tumors with immune suppressive microenvironment. More specifically, this combination therapy involves the treatment of cancer through immune checkpoint inhibitors and CpG-oligodeoxynucleotides.
    Type: Application
    Filed: September 6, 2021
    Publication date: March 9, 2023
    Inventors: Tsung-Hsien CHUANG, Jen-Chih TSENG, Jing-Xing YANG, Yi-Ling LIU